A Placebo-Controlled, Randomized, Clinical Trial of Azathioprine with & without Methylpred in MS
Neurol 39:1018-1026, Ellison,G.W.,et al, 1989
Chronic Progressive Multiple Sclerosis:Serial Magnetic Resonance Brain Imaging Over Six Months
Ann Neurol 26:248-256, Koopmans,R.A.,et al, 1989
Benign Versus Chronic Progressive Multiple Sclerosis:Magnetic Resonance Imaging Features
Ann Neurol 25:74-81, Koopmans,R.A.,et al, 1989
Correlation of Neuropsychological and MRI Findings in Chronic/Progressive Multiple Sclerosis
Neurol 38:1826-1829, Franklin,G.M.,et al, 1988
Cyclophosphamide"Pulses"in Chronic Progressive Multiple Sclerosis, A Preliminary Clinical Trial
Arch Neurol 44:828-832, Myers,L.W.,et al, 1987
Cyclophosphamide in Chronic Progressive Multiple Sclerosis, Maintenance vs Nonmaintenance Therapy
Arch Neurol 44:823-827, Goodkin,D.E.,et al, 1987
Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 387:1022-1032, Case 28-2022, 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Acute Flaccid Myelitis: Cause, Diagnosis, and Management
Lancet 394:334-397, Murphy, O.C.,et al, 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Sequential Bilateral Vision Loss in a Woman with Scalp Tenderness and Jaw Claudication
JAMA Neurol 78:878-879, Kaufman, A.R.,et al, 2021
Bornavirus Encephalitis Shows a Characteristic Magnetic Resonance Phenotype in Humans
Ann Neurol 88:723-735, Finck, T.,et al, 2020
Clinical Characteristics, Risk Factors, and Outcomes of POEMS Syndrome
Neurol 95:e268-e279, Keddie, S.,et al, 2020
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Diagnostic Tools for Immune Causes of Encephalitis
Clin Microbiol Infect 25:431-436, Lascano, A.M.,et al, 2019
Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Male with Hiccups and Quadriparesis
IJCMR 5:K28-K30, Tuteja,H.S.,et al, 2018
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Characteristics in Limbic Encephalitis with Anti-Adenylate Kinase 5 Autoantibodies
Neurol 88:514-524,508, Do, L. & Chanson, E., 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Neuromyelitis Optica Spectrum Disorders
UpToDate, May, Glisson,C.C., 2016
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Marburgs Variant of Multiple Sclerosis with Extensive Brain Lesions
Int J Neurol Neurother doi:10.23937/2378-3001/2/1/1027, Ludwig, A.,et al, 2015
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Subacute Sclerosing Panencephalitis
Adams & Victors Principles of Neurology, Chp 33, pg 766, Ropper, A.H.,et al, 2014
Progressive Cerebellar Ataxia and New-Onset Diabetes
Lancet 383:186, Kong, M.,et al, 2014
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013
Functional Impairment in Progressive Supranuclear Palsy
Neurol 80:380-384, Duff, K.,et al, 2013
Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Demographic and Clinical Characteristics of Malignant Multiple Sclerosis
Neurol 76:1996-2001, Gholipour, T.,et al, 2011
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy
Neurol 77:62-66, Schade van Westrum, S.M.,et al, 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Clinicopath Conf, The POEMS Syndrome, with Demyelinating Neuropathy and Solitary Pharmacytoma of Bone
NEJM 362:929-940, Case 7-2010, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Increased Tissue Damage and Lesion Volumes in African Americans with Multiple Sclerosis
Neurol 74:538-544,532, Weinstock-Guttman,B.,et al, 2010